In:
Scientific Reports, Springer Science and Business Media LLC, Vol. 12, No. 1 ( 2022-09-28)
Abstract:
Biliary-tract-carcinomas (BTC), pancreatic-ductal-adenocarcinomas (PDAC) and adenoidcystic-carcinomas (AC) have in common that they are traditionally treated with large clinical-target-volumes (CTV). The aim of this study is to examine the impact of pretreatment-[ 68 Ga]FAPI-PET/CT on target-volume-definition and posttreatment-[ 68 Ga]FAPI-PET/CT-response-assessment for BTC-, PDAC- and AC-patients referred to radiation-therapy. All consecutive BTC-, PDAC-, and AC-patients who received pretreatment-[ 68 Ga]FAPI-PET/CT±[ 18 F]FDG-PET/CT were included from 01.01.2020 to 01.03.2022. MTV and SUV max were separately generated based on [ 68 Ga]FAPI- and [ 18 F]FDG-PET/CT-images. A [ 68 Ga]FAPI- and [ 18 F]FDG-based-CTV was defined. Treatment-plans were compared. Treatment-response was reassessed by a second [ 68 Ga]FAPI-PET/CT and [ 18 F]FDG-PET/CT after treatment-completion. Intermodality comparison of lesion-to-background-ratios [SUV max_lesion /SUV mean_background ] for individual timepoints t 1 and t 2 revealed significant higher values for [ 68 Ga]FAPI compared to [ 18 F]FDG ( t 1 , p = 0.008; t 2 , p = 0.005). Intermodality comparison of radiation-therapy-plans showed that [ 68 Ga]FAPI-based planning resulted in D100% = 97.2% and V95% = 98.8% for the [ 18 F]FDG-MTV. [ 18 F]FDG-based-planning resulted in D100% = 35.9% and V95% = 78.1% for [ 68 Ga]FAPI-MTV. [ 18 F]FDG-based-planning resulted only in 2 patients in V95% 〉 95% for [ 68 Ga]FAPI-MTV, and in 1 patient in D100% 〉 97% for [ 68 Ga]FAPI-MTV. GTV-coverage in terms of V95% was 76.4% by [ 18 F]FDG-based-planning and 99.5% by [ 68 Ga]FAPI-based-planning. Pretreatment [ 68 Ga]FAPI-PET/CT enhances radiation-treatment-planning in this particular group of patients. While perilesional and tumoral follow-up [ 18 F]FDG-uptake behaved uniformly, perilesional and tumoral reaction may differ in follow-up [ 68 Ga]FAPI-imaging. Complementary [ 68 Ga]FAPI- and [ 18 F]FDG-imaging enhance treatment-response-assessment.
Type of Medium:
Online Resource
ISSN:
2045-2322
DOI:
10.1038/s41598-022-20447-6
Language:
English
Publisher:
Springer Science and Business Media LLC
Publication Date:
2022
detail.hit.zdb_id:
2615211-3
